GeneHealth - Your precision medicine

Mucopolysaccharidosis Mps-iii-a

Disease Details

Family Health Simplified

Buy Membership

Description: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is a rare genetic disorder characterized by the accumulation of heparan sulfate due to deficient activity of the enzyme heparan N-sulfatase, leading to progressive neurological deterioration and other systemic symptoms.
Type: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is transmitted in an autosomal recessive manner.
Signs And Symptoms: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is a rare genetic disorder that primarily affects the central nervous system. Below are the signs and symptoms:

1. **Developmental Delay**: Children may reach developmental milestones at a slower rate.
2. **Behavioral Problems**: Hyperactivity, aggression, and sleep disturbances are common.
3. **Cognitive Decline**: Progressive loss of cognitive skills, including memory and speech.
4. **Motor Dysfunction**: Coordination issues, muscle weakness, and eventual loss of mobility.
5. **Seizures**: Some individuals may experience seizures.
6. **Hearing and Vision Problems**: Progressive hearing loss and vision impairment.
7. **Physical Features**: Coarse facial features, thick hair, and stiff joints.
8. **Organomegaly**: Enlarged liver and spleen in some cases.
9. **Respiratory Issues**: Frequent infections and breathing difficulties.

These symptoms typically appear in early childhood and worsen over time. The disease is associated with a deficiency of the enzyme heparan-N-sulfatase, leading to accumulation of heparan sulfate in the body.
Prognosis: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is a progressive and severe neurodegenerative disorder. The prognosis is generally poor:

- Most children with MPS IIIA show developmental delays and cognitive decline starting around 2-6 years of age.
- The disease progresses to severe behavioral issues, loss of speech, and motor function decline.
- Life expectancy varies, but many affected individuals do not survive beyond their teenage years or early twenties.

"Nan" is not applicable or relevant information regarding prognosis.
Onset: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, typically presents its onset in early childhood, usually between ages 2 and 6.
Prevalence: The prevalence of Mucopolysaccharidosis type IIIA (MPS IIIA), which is also known as Sanfilippo syndrome type A, varies by population but is generally estimated to be between 0.28 and 4.1 per 100,000 live births.
Epidemiology: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is a rare autosomal recessive lysosomal storage disorder. The reported incidence varies globally, but it is estimated to occur in approximately 1 in 70,000 to 1 in 200,000 live births. Due to its rarity, many regions may not have precise epidemiological data. The disorder primarily affects children, with symptoms typically appearing between ages 2 and 6.
Intractability: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is considered intractable in that it currently lacks a cure and standard treatment primarily focuses on managing symptoms and providing supportive care. Research into potential treatments, including enzyme replacement therapy, gene therapy, and other experimental approaches, is ongoing.
Disease Severity: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is generally severe. It is a progressive disorder that primarily affects the central nervous system, leading to neurodegeneration. Symptoms usually present in early childhood and include developmental delay, behavioral problems, sleep disturbances, and loss of previously acquired skills. The progression of the disease often results in severe cognitive decline, loss of mobility, and early mortality, typically in adolescence or early adulthood.
Pathophysiology: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is a lysosomal storage disorder caused by a deficiency in the enzyme heparan N-sulfatase. This enzyme is responsible for the degradation of heparan sulfate, a glycosaminoglycan. The deficiency leads to the accumulation of heparan sulfate in lysosomes, causing cellular and tissue damage. The pathophysiology primarily involves progressive neurological deterioration due to accumulation in the central nervous system, leading to symptoms like developmental delay, behavioral problems, and loss of motor skills. Peripheral organ involvement can also occur but is less pronounced.
Carrier Status: Mucopolysaccharidosis IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is an inherited disorder caused by a deficiency of the enzyme heparan N-sulfatase. It is inherited in an autosomal recessive manner. Carrier status for MPS IIIA means that an individual has one mutated copy of the gene responsible for the condition (SGSH gene) and one normal copy. Carriers typically do not exhibit symptoms of the disease but can pass the mutated gene to their offspring. If both parents are carriers, there is a 25% chance with each pregnancy that the child will inherit two mutated copies of the gene and thus be affected by MPS IIIA.
Mechanism: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is caused by a deficiency in the enzyme heparan N-sulfatase (SGSH). This enzyme is responsible for breaking down heparan sulfate, a type of glycosaminoglycan (GAG), within lysosomes.

**Mechanism:**
1. **Enzyme Deficiency:** The genetic mutation in the SGSH gene leads to a lack or malfunction of the heparan N-sulfatase enzyme.
2. **Substrate Accumulation:** As a result, heparan sulfate is not adequately degraded and accumulates within lysosomes.
3. **Cellular Dysfunction:** This accumulation disrupts cellular function, primarily affecting cells in the central nervous system.
4. **Clinical Manifestations:** The build-up of heparan sulfate in cells leads to progressive neurodegeneration, cognitive decline, behavioral issues, and other systemic symptoms characteristic of MPS IIIA.

**Molecular Mechanisms:**
1. **Gene Mutation:** Mutations in the SGSH gene located on chromosome 17 (17q25.3) are responsible for the defective enzyme production.
2. **Loss of Function:** These mutations typically result in a missense, nonsense, or frameshift mutations that cause a loss of functional enzyme.
3. **Lysosomal Storage Disorder:** The disease is classified as a lysosomal storage disorder because the primary pathology involves the storage of unmetabolized substrates within the lysosomes.
4. **Secondary Cellular Effects:** The accumulation of heparan sulfate and other secondary storage materials can lead to oxidative stress, inflammation, and apoptosis (cell death), further contributing to cellular and tissue damage.

Understanding these mechanisms is crucial for developing targeted therapies aimed at either restoring enzyme function, reducing the accumulation of heparan sulfate, or mitigating the secondary effects of substrate storage.
Treatment: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, currently has no cure and treatment is primarily supportive. The focus is on managing symptoms and improving the quality of life. This may include physical therapy, speech therapy, and educational support. Enzyme replacement therapy and gene therapy are areas of ongoing research but are not yet standard treatments. Regular follow-up with a multidisciplinary team that includes neurologists, geneticists, and other specialists is essential for optimal management.
Compassionate Use Treatment: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is a rare genetic disorder caused by deficiencies in the enzyme heparan N-sulfatase. Treatments for MPS IIIA are limited and primarily focus on managing symptoms. However, compassionate use treatments, off-label, or experimental therapies may be considered in certain cases.

1. **Compassionate Use Treatment**:
- Compassionate use, also known as expanded access, allows patients with serious or life-threatening conditions to gain access to investigational drugs outside of clinical trials. Specific options for MPS IIIA need to be discussed with a healthcare provider and may involve gene therapy or enzyme replacement therapy.

2. **Off-label Treatments**:
- Some medications may be used off-label to manage symptoms associated with MPS IIIA, such as anticonvulsants for seizures, psychotropic drugs for behavioral issues, and pain relievers for discomfort.

3. **Experimental Treatments**:
- Gene Therapy: Research into gene therapy aims to introduce a functional copy of the faulty gene responsible for MPS IIIA. Early-phase clinical trials are ongoing.
- Enzyme Replacement Therapy (ERT): Efforts are being made to develop ERT for MPS IIIA, where the deficient enzyme is replaced by a recombinant version.
- Substrate Reduction Therapy (SRT): This involves drugs that can potentially reduce the accumulation of glycosaminoglycans (GAGs) in cells.

Always consult healthcare providers for the most current and personalized information regarding treatments for MPS IIIA.
Lifestyle Recommendations: For Mucopolysaccharidosis type IIIA (MPS IIIA), lifestyle recommendations aim to improve the quality of life and manage symptoms. Here are some key points:
- **Regular Medical Check-ups:** Frequent visits to healthcare providers for monitoring disease progression and managing complications.
- **Physical Therapy:** Helps maintain mobility and manage joint stiffness.
- **Occupational Therapy:** Assists with daily activities and helps maintain independence.
- **Speech Therapy:** Supports communication skills, which can be affected as the disease progresses.
- **Nutritional Management:** A balanced diet to ensure proper nutrition and manage gastrointestinal issues.
- **Safety Measures:** Adapting the living environment to prevent injuries, as patients might have impaired coordination.
- **Support Groups and Counseling:** Emotional and mental health support for both patients and caregivers.

It's crucial to develop a comprehensive care plan tailored to the individual needs of the patient in consultation with a multidisciplinary team.
Medication: For Mucopolysaccharidosis type IIIA (MPS IIIA or Sanfilippo syndrome type A), there are currently no FDA-approved medications specifically for treating the underlying cause of the disease. Treatment primarily focuses on managing symptoms and supportive care. Clinical trials are ongoing to explore potential therapies, including enzyme replacement therapy (ERT), gene therapy, and substrate reduction therapy.
Repurposable Drugs: Mucopolysaccharidosis type IIIA (MPS-IIIA), also known as Sanfilippo syndrome type A, is a rare lysosomal storage disorder. While specific repurposable drugs for MPS-IIIA may still be under investigation, some existing treatments for similar lysosomal storage diseases or related pathways could potentially offer benefits. These include:

1. **Genistein** – A naturally occurring isoflavone found in soy products, showing potential in reducing glycosaminoglycan (GAG) accumulation.
2. **Anti-inflammatory agents** – Such as non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids, to manage symptoms and inflammation.
3. **Antioxidants** – To reduce oxidative stress, which may contribute to disease pathology.
4. **Substrate reduction therapy (SRT)** – Drugs like miglustat, used in some other lysosomal storage disorders, might have a role.

Research is ongoing to identify and confirm effective treatment options, and newer therapeutic approaches like enzyme replacement therapy (ERT) or gene therapy are being explored. It is important to consult with a healthcare provider specializing in metabolic disorders for the most current treatment options.
Metabolites: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is characterized by the accumulation of heparan sulfate due to a deficiency in the enzyme heparan N-sulfatase (sulfamidase). This leads to the metabolites primarily being heparan sulfate and its partially degraded fragments. These metabolites accumulate within lysosomes, resulting in cellular and tissue damage.
Nutraceuticals: For Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, there is limited evidence on the effectiveness of nutraceuticals in treatment or management. Nutraceuticals are products derived from food sources with extra health benefits in addition to the basic nutritional value found in foods. Currently, the primary treatments focus on managing symptoms and complications rather than curing the disease.

There is ongoing research exploring various approaches, including enzyme replacement therapy, gene therapy, and substrate reduction therapy, but none of these approaches have yet provided a definitive cure.

It is important to consult with a healthcare professional before initiating any nutraceutical regimen, as MPS IIIA requires tailored medical management.
Peptides: Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A, is a lysosomal storage disorder caused by a deficiency in the enzyme heparan N-sulfatase (SGSH). This enzyme deficiency leads to the accumulation of heparan sulfate in the body, resulting in various symptoms, including severe neurological decline.

Given your keywords "peptides, nan," it's worth noting that peptide-based therapies and nanotechnologies are areas of research interest for treating MPS IIIA. Researchers are exploring how these methods can enhance the delivery of therapeutics across biological barriers, particularly the blood-brain barrier, to effectively target and treat neurological symptoms in MPS IIIA patients. Nanoparticles may also assist in delivering enzyme replacement therapies or gene therapies more efficiently. These investigational approaches aim to address the underlying enzyme deficiency and reduce the accumulation of harmful substances in the cells.